carboplatin + temozolomide + vincristine

This is a combination chemotherapy regimen consisting of three small molecule drugs—carboplatin, temozolomide, and vincristine. Each drug has a distinct mechanism of action targeting cancer cells: - **Carboplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA synthesis and function, leading to apoptosis in rapidly dividing tumor cells. - **Temozolomide** is an oral alkylating agent that methylates DNA at the O6 and N7 positions of guanine residues, resulting in cytotoxicity primarily through induction of DNA damage. - **Vincristine** is a vinca alkaloid that binds to tubulin and inhibits microtubule formation during mitosis, arresting cell division. The combination leverages these complementary mechanisms to enhance antitumor efficacy. This regimen has been investigated particularly for pediatric low-grade gliomas and other brain tumors where multi-agent chemotherapy may be required due to tumor progression or recurrence[1][5]. The rationale for combining these agents lies in their non-overlapping toxicities and synergistic effects on tumor cell kill[5].